We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+6.63%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$256M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow
% of AUM
96.01%
Top 10 Holdings %
Top 10 Hldgs %
29.36%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$7.75M |
| 3 |
Gilead Sciences
GILD
|
+$7.59M |
| 4 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$7.28M |
| 5 |
Biogen
BIIB
|
+$6.98M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.65% |
| 2 | Financials | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Celldex Therapeutics
CLDX
$3.28B
| $2.18M | 0.85% |
+6,000
| New | +$2.31M |
|
52
Nektar Therapeutics
NKTR
$2.58B
| $2.16M | 0.84% |
+12,667
| New | +$2.04M |
|
53
Integra LifeSciences
IART
$1.34B
| $2.15M | 0.84% |
+110,091
| New | +$2.02M |
|
54
Exelixis
EXEL
$13.4B
| $2.15M | 0.84% |
+350,000
| New | +$1.93M |
|
55
Acadia Pharmaceuticals
ACAD
$5.03B
| $2.12M | 0.83% |
+85,000
| New | +$2.01M |
|
56
McKesson
MCK
$101B
| $2.1M | 0.82% |
+13,000
| New | +$2M |
|
57
Centene
CNC
$32.5B
| $2.06M | 0.81% |
+140,000
| New | +$2.09M |
|
58
Ligand Pharmaceuticals
LGND
$6.36B
| $2M | 0.78% |
+60,914
| New | +$1.98M |
|
59
Revvity
RVTY
$12.8B
| $1.85M | 0.73% |
+45,000
| New | +$1.72M |
|
|
ARRY
60
DELISTED
Array Biopharma Inc
ARRY
| $1.8M | 0.71% |
+360,000
| New | +$1.96M |
|
61
Eli Lilly
LLY
$1.06T
| $1.78M | 0.7% |
+35,000
| New | +$1.75M |
|
62
Community Health Systems
CYH
$423M
| $1.77M | 0.69% |
+54,450
| New | +$1.87M |
|
|
AUXL
63
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $1.76M | 0.69% |
+85,000
| New | +$1.6M |
|
|
BCR
64
DELISTED
CR Bard Inc.
BCR
| $1.74M | 0.68% |
+13,000
| New | +$1.71M |
|
|
ABMD
65
DELISTED
Abiomed Inc
ABMD
| $1.74M | 0.68% |
+65,000
| New | +$1.61M |
|
66
Supernus Pharmaceuticals
SUPN
$2.77B
| $1.7M | 0.66% |
+225,000
| New | +$1.57M |
|
67
Myriad Genetics
MYGN
$312M
| $1.69M | 0.66% |
+80,759
| New | +$2.04M |
|
|
AGN
68
DELISTED
Allergan plc
AGN
| $1.68M | 0.66% |
+10,000
| New | +$1.56M |
|
|
HOLX
69
DELISTED
Hologic
HOLX
| $1.61M | 0.63% |
+72,000
| New | +$1.59M |
|
|
IMGN
70
DELISTED
Immunogen Inc
IMGN
| $1.47M | 0.57% |
+100,000
| New | +$1.54M |
|
|
ELGX
71
DELISTED
Endologix Inc
ELGX
| $1.41M | 0.55% |
+8,103
| New | +$1.39M |
|
|
OREX
72
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $1.41M | 0.55% |
+25,000
| New | +$1.4M |
|
|
CPHD
73
DELISTED
Cepheid Inc
CPHD
| $1.4M | 0.55% |
+30,000
| New | +$1.27M |
|
74
Haemonetics
HAE
$4B
| $1.26M | 0.49% |
+30,000
| New | +$1.23M |
|
|
MTEM
75
DELISTED
Molecular Templates, Inc.
MTEM
| $1.17M | 0.46% |
+1,515
| New | +$1.14M |
|
Similar funds
PS
ACM
AR
KCP
BCM
RIM
GCM
CL
Rhenman & Partners Asset Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Rhenman & Partners Asset Management, which disclosed 84 positions worth $256M. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, followed by Financials.
- Rhenman & Partners Asset Management's largest Q4 2013 buy was Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.
- Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $256M portfolio in Q4 2013.
- Rhenman & Partners Asset Management disclosed 84 positions in Q4 2013, its first 13F filing on record.
Based on Rhenman & Partners Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.